CVS Health stock: Bernstein SocGen cuts target to 106 US dollars
Published on 11/13/2026 at 16:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view after strong quarter
- The firm kept an Outperform rating while reducing its valuation target.
- Bernstein SocGen cited managed-care potential and a simpler structure after separation.
- Medical costs and possible dis-synergies remain risks for investors.
Bernstein SocGen lowered its price target for CVS Health to 106 US dollars from 112 US dollars on Friday, November 13, 2026, while keeping an Outperform rating, according to Investing.com. The brokerage pointed to attractive exposure to a managed-care turnaround and potential stabilization in retail pharmacy and pharmacy benefit manager earnings.
Bernstein said Aetna continued to outperform, helped by a better-than-expected medical loss ratio. Retail pharmacy results were broadly in line with expectations, while the pharmacy benefit manager and health services segment exceeded the firm's expectations on stronger revenue growth.
Separation brings opportunity and risk
The planned separation received a positive assessment because it could give management a simpler structure and sharpen the investment case. Bernstein also warned of possible dis-synergies, including weaker network steering into CVS stores and lower pharmaceutical purchasing scale.
CVS Health stock traded at 80.49 euros on Lang & Schwarz at 16:10 CET on Friday, November 13, 2026. The analyst view leaves the planned separation and the outlook for medical costs as key issues for investors weighing the company's managed-care and pharmacy businesses.
CVS Health Corp. at a glance
- Company: CVS Health Corp.
- ISIN: US1266501006
- Ticker: CVS
- Price: 80.49 euros at 16:10 CET on November 13, 2026
- Trading venue: Lang & Schwarz
US equities are covered in the current market reports.
More news and analyses on CVS Health stock.
